Compare GRWG & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRWG | NRXS |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.7M | 78.9M |
| IPO Year | 2015 | 2023 |
| Metric | GRWG | NRXS |
|---|---|---|
| Price | $1.62 | $7.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 482.7K | 159.3K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.22 | 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,365,479.00 | $3,569,282.00 |
| Revenue This Year | $5.09 | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 142.51 | 32.89 |
| 52 Week Low | $0.93 | $2.20 |
| 52 Week High | $2.40 | $9.33 |
| Indicator | GRWG | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 42.63 |
| Support Level | $1.44 | $6.51 |
| Resistance Level | $1.83 | $7.85 |
| Average True Range (ATR) | 0.10 | 0.47 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 42.11 | 14.87 |
GrowGeneration Corp owns and operates specialty retail stores focused on hydroponic and organic gardening. The company markets and distributes nutrients, growing media, indoor and greenhouse lighting, ventilation systems, and related accessories. It operates through two reportable segments: Cultivation and Gardening, which includes its hydroponic and organic gardening business, and Storage Solutions, which includes its benching, racking, and storage solutions operations. The company generates revenue mainly from the sale of proprietary and non-proprietary products through retail stores, e-commerce platforms, wholesale distribution, and commercial sales, along with the sale and installation of commercial fixtures.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).